Karen GEOFFROY

Dr. Karen GEOFFROY

CHUM Research Center, Montréal, Quebec, Canada
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
Dominic G. RoyDominic G. Roy
Dominic G. Roy
KGKaren GEOFFROY
Karen GEOFFROY
MMM. Marguerie
M. Marguerie
SKS. T. Khan
S. T. Khan
NMN. T. Martin
N. T. Martin
MBM.-C. Bourgeois-Daigneault
M.-C. Bourgeois-Daigneault
By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two different viruses expressing the same tumor antigen to prime and boost anti-tumor immunity. By providing the additional advantage of directly killing cancer cells, oncolytic viruses (OVs) constitute ideal platforms for such treatment strategy. However, given that the targeted tumor antigen is encoded into the viral genomes, its production requires robust infection and therefore, the vaccination efficiency partially depends on the unpredictable and highly variable intrinsic sensitivity of each tumor to OV infection. In this study, we demonstrate that anti-cancer vaccination using OVs (Adenovirus (Ad), Maraba virus (MRB), Vesicular stomatitis virus (VSV) and Vaccinia virus (VV)) co-administered with antigenic peptides is as efficient as antigen-engineered OVs and does not depend on viral replication. Our strategy is particularly attractive for personalized anti-cancer vaccines targeting patient-specific mutations. We suggest that the use of OVs as adjuvant platforms for therapeutic anti-cancer vaccination warrants testing for cancer treatment.

1 December 2020 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
KGKaren GEOFFROY
Karen GEOFFROY
MBMarie-Claude Bourgeois-Daigneault
Marie-Claude Bourgeois-Daigneault

15 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CFClaire Franczak
Claire Franczak
AWAndréa Witz
Andréa Witz
KGKaren GEOFFROY
Karen GEOFFROY
JDJessica Demange
Jessica Demange
MRMarie Rouyer
Marie Rouyer
AHAlexandre Harlé
Alexandre Harlé
Cell-free DNA detection is becoming a surrogate assay for tumor genotyping. Biological fluids often content a very low amount of cell-free tumor DNA and assays able to detect very low allele frequency mutant with a few quantities of DNA are required. We evaluated the ability of the fully-automated molecular diagnostics platform Idylla for the detection of KRAS, NRAS and BRAF hotspot mutations in plasma from patients with metastatic colorectal cancer (mCRC). First, we evaluated the limit of detection of the system using two set of laboratory made samples that mimic mCRC patient plasma, then plasma samples from patients with mCRC were assessed using Idylla system and BEAMing digital PCR technology. Limits of detection of 0.1%, 0.4% and 0.01% for KRAS, NRAS and BRAF respectively have been reached. With our laboratory made samples, sensitivity up to 0.008% has been reached. Among 15 patients’ samples tested for KRAS mutation, 2 discrepant results were found between Idylla and BEAMing dPCR. A 100% concordance between the two assays has been found for the detection of NRAS and BRAF mutations in plasma samples. The Idylla system does not reach as high sensitivity as assays like ddPCR but has an equivalent sensitivity to modified NGS technics with a lower cost and a lower time to results. These data allowed to consider the Idylla system in a routine laboratory workflow for KRAS, NRAS and BRAF mutations detection in plasma.

19 August 2019 in OncoImmunology
Verified
Journal Article
Open access
VMVictor Mullins-Dansereau
Victor Mullins-Dansereau
GPGrégory Petrazzo
Grégory Petrazzo
KGKaren GEOFFROY
Karen GEOFFROY
DBDelphine Béland
Delphine Béland
MBMarie-Claude Bourgeois-Daigneault
Marie-Claude Bourgeois-Daigneault
Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).

4 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KGKaren GEOFFROY
Karen GEOFFROY
PLPatrick Laplante
Patrick Laplante
SCSylvie Clairefond
Sylvie Clairefond
FAFeryel Azzi
Feryel Azzi
Dominique TrudelDominique Trudel
Dominique Trudel
JCJean François Cailhier
Jean François Cailhier
Milk fat globule-epidermal growth factor-8 (MFG-E8) is a glycoprotein secreted by different cell types, including apoptotic cells and activated macrophages. MFG-E8 is highly expressed in a variety of cancers and is classically associated with tumor growth and poor patient prognosis through reprogramming of macrophages into the pro-tumoral/pro-angiogenic M2 phenotype. To date, correlations between levels of MFG-E8 and patient survival in prostate and renal cancers remain unclear. Here, we quantified MFG-E8 and CD68/CD206 expression by immunofluorescence staining in tissue microarrays constructed from renal (n = 190) and prostate (n = 274) cancer patient specimens. Percentages of MFG-E8-positive surface area were assessed in each patient core and Kaplan–Meier analyses were performed accordingly. We found that MFG-E8 was expressed more abundantly in malignant regions of prostate tissue and papillary renal cell carcinoma but was also increased in the normal adjacent regions in clear cell renal carcinoma. In addition, M2 tumor-associated macrophage staining was increased in the normal adjacent tissues compared to the malignant areas in renal cancer patients. Overall, high tissue expression of MFG-E8 was associated with less disease progression and better survival in prostate and renal cancer patients. Our observations provide new insights into tumoral MFG-E8 content and macrophage reprogramming in cancer.

10 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KGKaren GEOFFROY
Karen GEOFFROY
MVMelissa Viens
Melissa Viens
EKEmma Mary Kalin
Emma Mary Kalin
ZBZied Boudhraa
Zied Boudhraa
Dominic G. RoyDominic G. Roy
Dominic G. Roy
MBMarie-Claude Bourgeois-Daigneault
Marie-Claude Bourgeois-Daigneault
Background/Objectives: Ovarian cancer is the deadliest gynecologic cancer, and with the majority of patients dying within the first five years of diagnosis, new therapeutic options are required. The small guanosine triphosphatase (GTPase) Ras-related nuclear protein (Ran) has been reported to be highly expressed in high-grade serous ovarian cancers (HGSOCs) and associated with poor outcomes. Blocking Ran function or preventing its expression were shown to be promising treatment strategies, however, there are currently no small molecule inhibitors available to specifically inhibit Ran function. Interestingly, a previous study suggested that the Vesicular stomatitis virus (VSV) could inhibit Ran activity. Given that VSV is an oncolytic virus (OV) and, therefore, has anti-cancer activity, we reasoned that oncolytic VSV (oVSV) might be particularly effective against ovarian cancer via Ran inhibition. Methods: We evaluated the sensitivity of patient-derived ovarian cancer cell lines to oVSV, as well as the impact of oVSV on Ran and vice versa, using overexpression systems, small interfering RNAs (siRNAs), and drug inhibition. Results: In this study, we evaluated the interplay between oVSV and Ran and found that, although oVSV does not consistently block Ran, increased Ran activation allows for better oVSV replication and tumor cell killing. Conclusions: Our study reveals a positive impact of Ran on oVSV sensitivity. Given the high expression of Ran in HGSOCs, which are particularly aggressive ovarian cancers, our data suggest that oVSV could be effective against the deadliest form of the disease.